Trial closed October 2022.
Canine Mast Cell Tumor
Evaluation of Combined Chlorambucil and Toceranib for Treatment of Canine Mast Cell Tumors
Purpose of the study:
- To evaluate the safety and antitumor activity of combination treatment with toceranib and metronomic chlorambucil given to dogs with measurable mast cell tumor (MCT)
Primary Eligibility Criteria:
- Dogs with a confirmed diagnosis of mast cell tumor that is at least 1 cm in diameter
- Good function of liver and kidneys, acceptable blood cell counts, and free of severe underlying disease
- Two-week washout from chemotherapy, 6 weeks from radiation therapy, 72 hours from steroids and cannot have been on steroids for >2 weeks; no prior treatment with toceranib or chlorambucil (or similar drugs)
- Pets must come to CSU for all visits related to the clinical trial
- Once enrolled, dogs will start treatment first with chlorambucil and then toceranib two weeks later; this study does not have a placebo group – all dogs will receive treatment with toceranib and chlorambucil.
- Dogs will come for visits every 2 weeks for physical exam, tumor measurements, and blood +/- urine collection for the 1st 8 weeks then every 6 weeks
- Dogs will continue on study as long as the treatment is tolerated and the tumor is not growing
- Follow appointment schedule required by study protocol
- Administer oral medications at home to your pet
- Costs associated with the initial exam fee, other tests to confirm study eligibility, the cost of chlorambucil, and ancillary medications (diphenhydramine [Benadryl] and omeprazole [Prilosec])
- The study will cover the costs of initial testing (lymph node cytology, ultrasound, cytology of the tumor), genetic testing of the tumor, recheck examinations, blood and urine tests, and toceranib
If you have further questions about any of our clinical trials, please submit an online consult form. Your consult will then be directed to our trials team. Requests are typically returned within 5 business days.